[COMPANY_001] Institutes for BioMedical Research
CGF166
Clinical Trial Protocol CCGF166X2201
A three -part, multicenter, o pen label, single dose study  
toassess the safety, tolerability , and efficacy  of intra -
laby[CONTACT_351962] (IL) CGF166 in patients w ith severe-to-
profound hearing loss
Document type: Amended Protocol Version
Version number: v06 (Clean)
Study phase: I/II
Release date: 30-Apr-2019
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
[COMPANY_001] Confidential Page 2
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Notification of serious adverse events
A serious adverse event (SAE) is any event which is fatal or life-threatening, which requires 
or prolongs hospi[INVESTIGATOR_059], which is sig nificantly or permanentl y disabling or incapacitating, 
which constitutes a congenital anomal y or a birth defect, or which is medically  significant, 
may jeopardize the patient and may require medical or surgical intervention to prevent one of 
the outcomes l isted above.
Any SAE occurring in a patient from consent until 30 days after stoppi[INVESTIGATOR_351950] (defined as time of last dose of study  drug taken or last visit whichever is the 
later) must be reported either on the paper SAE report form or via the electronic SAE form 
within the clinical data capture s ystem (where available).
For SAEs reported using the paper SAE report form , the investigator will ensure that the 
form is completed and faxed by [CONTACT_351963] (CMO & PS) Department within [ADDRESS_437789] be kept with the case report forms at the study 
site.
For SAEs recorded electronically in the [COMPANY_001] clinical data capture system, information 
should be entered, saved and e-signed within 24 hours of awareness of the SAE . 
These data will automatically  be submitted to CMO & PS Depart ment .
More details in Section 7 of this protocol.
Fax numbers of local [COMPANY_001] Chief Medical Office and Patient Safety  (CMO & 
PS)Departments
North America Fax (+ 1) [PHONE_7279]
(+ 1) [PHONE_7280] (toll free number)
Any update to the [COMPANY_001] CMO & PS or personnel information required during the course of 
the study  will be communicated directl y to the relevant Investigator site(s); a specific protocol 
amendment should not be required.
[COMPANY_001] Confidential Page 3
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Table of contents
Notification of serious adverse events ................................................................................. [ADDRESS_437790] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol sy nopsis ............................................................................................................... 22
Assessment schedule ......................................................................................................... 27
1Introduction ....................................................................................................................... 29
1.1 Background ............................................................................................................ 29
1.1.1 Relevant data summary ......................................................................... 29
1.2 Study  purpose ........................................................................................................ 37
2Study  objectives ................................ ................................ ................................ ................. 38
2.1 Primary  objective(s) ............................................................................................... 38
2.2 Secondary  objective(s) ........................................................................................... 38
2.3 Exploratory  objective(s) ........................................................................................ 38
3Investigational plan ................................ ................................ ................................ ........... 39
3.1 Study  design ........................................................................................................... 39
3.2 Rationale of study  design ....................................................................................... 44
3.3 Rationale of dose/regimen, duration of treatment ................................................. 44
3.4
Rationale for choice of comparator ....................................................................... 45
3.5 Purpose and timing of interim anal yses / design adaptations ................................ 45
3.6 Risks and b
enefits .................................................................................................. 46
3.6.1 Risks of clinical assessments ................................................................ 46
3.6.2 Risks of general anesthesia and stapedotom y surgery .......................... 46
3.6.3
Risks of administering volume and CGF166 into the inner ear............ 46
3.6.4 Potential benefits of CGF166 administration ........................................ 47
4Population ................................ ................................ ................................ .......................... 47
4.1 Inclusion criteria .................................................................................................... 48
Commercially Confidential Information
[COMPANY_001] Confidential Page 4
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
4.2 Exclusion criteria ................................ ................................ ................................ ...48
5Treatment ........................................................................................................................... 50
5.1
Protocol requested treatment ................................................................................. 50
5.1.1 Investigational treat
ment ....................................................................... 50
5.1.2 Additional study  treatment .................................................................... 50
5.2 Treatment arms ...................................................................................................... 50
5.3 Treatment assignment ............................................................................................ 51
5.4 Treatment blinding ................................................................................................. 51
5.5 Treating the patient ................................................................................................ 51
5.5.1 Treatment / Patient numbering .............................................................. [ADDRESS_437791] -study  treatment .......................................... 56
5.5.13 Early study termination ......................................................................... 56
6
Visit assessments............................................................................................................... 56
6.1 Dietary , fluid and other restrictions ................................ ................................ .......57
6.2 Patient demographics / other baseline characteristics ........................................... 57
6.3 Treatment exposure and compliance ..................................................................... 57
6.4 Efficacy  assessments ............................................................................................. 57
6.4.1 Auditory  assessments ............................................................................ 58
6.4.2 Vestibular assessments .......................................................................... 59
6.5 Safet y
..................................................................................................................... 61
6.5.1 Physical examination ............................................................................ 61
6.5.2 Vital signs .............................................................................................. 61
6.5.3 Height and weight ................................................................................. 61
6.5.4 Laboratory  evaluations .......................................................................... 61
Commercially Confidential Information
[COMPANY_001] Confidential Page 5
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
6.5.5 Electrocardiogram (ECG) ..................................................................... 63
6.5.6 Hearing and balance assessments
.......................................................... 63
6.5.7 Magnetic resonance Imaging (MRI) ..................................................... [ADDRESS_437792]
............................................................................... 71
8.5 Adjudication Committee ........................................................................................ 71
9Data analy sis...................................................................................................................... 72
9.1 Analy sis sets .......................................................................................................... 72
9.2
Patient demographics and other baseline characteristics....................................... 72
9.3 Treatments (stud y drug, rescue medication, other concomitant therapi[INVESTIGATOR_014], 
compliance) ............................................................................................................ 72
9.4 Analy sis of the primary  variable(s) ....................................................................... 72
9.4.1 Variable(s) ............................................................................................. 72
9.4.2 Statistical model, hy pothesis, and method of analysis .......................... 72
9.4.3 Handling of missing values/censoring/discontinuations ....................... 73
9.4.4 Supportive anal yses............................................................................... 73
9.5 Analy sis of secondary   variables
.................................................. 73
9.5.1 Efficacy ................................................................................................. 73
9.5.2
Safety..................................................................................................... 73
Commercially Confidential Information
Commercially Confidential InformationCommercially 
Confidential 
Information

[COMPANY_001] Confidential Page 6
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
9.6 Sample size calculation................................ ................................ .......................... 74
9.7 Power for anal ysis of key secondary  variables ...................................................... 75
9.8 Interim anal yses..................................................................................................... 75
10
Ethical consideration ......................................................................................................... 75
10.1 Regulatory
 and ethical compliance ........................................................................ 75
10.2 Informed consent procedures
................................................................................. 75
10.3 Responsibilities of the investigator and IRB/IEC .................................................. 76
10.4 Publication of study  protocol and results ............................................................... 76
11Protocol adherence ............................................................................................................ 77
11.1 Protocol amendments ............................................................................................. 77
12References ......................................................................................................................... 78
13Appendix 1: Sample L og table –all matrices ................................................................... 80
15Appendix 3: L iver event definitions and follow -up requirements ................................ ....[ADDRESS_437793] of fi gures
Figure 3 -
1 Study  design ................................ ................................ .......................... 40
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 7
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
List of abbreviations
ABR Auditory  brainstem evoked response
Ad5 Adenovirus serot ype [ADDRESS_437794] disc – read onl y memory
CFR Code of Federal Regulation
CK creatinine kinase
CRF Case Report/Record Form (paper or electronic)
CO 2 carbon dioxide
COWS Cool –Opposite, Warm –Same
CRO Contract Research Organization
CT Computerized tomography
CV coefficient of variation
dB decibels
DP Directional preponderance
DPT Distortion product
DPOAE Distortion product otoacoustic emissions
Commercially Confidential Information
[COMPANY_001] Confidential Page 8
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
DSMB Data Safety  Monitoring Board  
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
ELISA Enzy me-linked immunosorbent assay
FDA Food and Drug Administration
GCP Good Clinical Practice
GFAP Glial fibrillary  acidic protein
GFP Green fluorescent p rotein
GV11 Adenovector backbone used for CGF166
Hath1 Human atonal Protein
h hour
HINT Hearing -in-noise test
HIV human immunodeficiency virus
HL Hearing Loss
ICH International Conference on Harmonization of Technica l Requirements for 
Registration of Pharmaceuticals for Human Use
IDPN 3’, 3’ -iminodipropi[INVESTIGATOR_351951] -laby[CONTACT_351962]
i.v. intravenous
IRB Institutional Review Board
kHz Kilohertz
LDH lactate deh ydrogenase
LLQ lower limit of quantification
LLN lower limit of normal
LO Laby[CONTACT_351964](s)
mL milliliter(s)
MRI Magnetic resonance imaging
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 9
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
PTA Pure t one a verage
RBC red blood cell(s)
REB Research Ethics Board
SAE serious adverse event
SCM sternocleidomastoid muscle
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic p yruvic transaminase
SD standard deviation
SPV slow phase velocit y
TBL total bilirubin
TRQ Tinnitus reaction questio nnaire
ULN upper limit of normal
ULQ upper limit of quantification
VCR vestibulocollic reflex
vHIT video Head Impulse Test
VOR Vestibulo
-ocular reflex
vp Viral particles
WBC white blood cell(s)
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 10
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Glossary  of terms
Assessment A procedure used to generate data required b y the study .
Enrollment Point/time of patient entry into the study ; the point at which 
informed consent must be obtained (i.e., prior to starting any 
of the procedures described in the protocol).
Investigational drug The study  drug whose properties are being tested in the study ; 
this definition is consistent with US CFR 21 Section 312.3 
and is synony mous with “investigational new drug” or 
“investigational medicinal product”.
Investigational treatment All investigational drug(s) whose properties are being tested 
in the study  as well as their associated treatment controls.
This includes any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved 
dosage or tested in a fixed combination.
Investigational treatment generall y does not include other 
treatments administered as concomitant background therap y 
required or allowed by [CONTACT_351965]/dosage.
Part A major subdivision of the study  timeline; begins and ends 
with major study  m ilestones such as enrollment, 
randomization, completion of treatment, etc.
Patient An individual who has consen ted to participate in this study . 
The term Patient may be used to describe either a health y 
volunteer or a patient.
Patient number A number assigned to each patient who enrolls in the study . 
When combined with the center number, a unique identifier is 
created for each patient in the study .
Period A minor subdivision of the study  timeline; divides phases into 
smaller functional segments such as screening, baseline, 
titration, washout, etc.
Personal DataSubject information collected by [CONTACT_351966]. 
This data includes subject identifier information, study  
information and biological samples.
Premature patient 
withdrawalPoint/time when the patient exits from the study  prior to the 
planned completion of all study  drug administration and 
assessments; at this time all study  drug administration is 
discontinued and no further assessments are planned.
[COMPANY_001] Confidential Page 11
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Study  completion Point/time at which the patient came in for a final evaluation 
visit o r when study  drug was discontinued whichever is later.
Study  drug discontinuation Point/time when patient permanentl y stops taking study  drug 
for any reason; may or may not also be the point/time of 
premature patient withdrawal.
Study  drug/treatment Any drug (or combination of drugs) administered to the 
patient as part of the required study  procedures; includes 
investigational drug, active drug run-ins or background 
therap y.
Treatment number A unique identifier assigned to each treated patient, 
correspon ding to a specific treatment arm assignment.
Variable Information used in the data analysis; derived directly  or 
indirectly  from data collected using specified assessments at 
specified timepoints.
Withdrawal of consent 
(WoC)Withdrawal of consent from the study  occurs only when a 
subject does not want to participate in the study  any longer, 
and does not allow an y further collection of personal data
[COMPANY_001] Confidential Page 12
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 13
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 14
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 15
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 16
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 17
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 18
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 19
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 20
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 22
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Protocol sy nopsis
Protocol number CCGF166X2201
Title A three -part, multicenter, open label, single dose study to assess the safety, 
tolerability, and efficacy  of intra-laby[CONTACT_351962] (IL) CGF166 in patients with 
severe- to-profound hearing loss
Brief title A study  of the gene therapy CGF166 in patients with severe-to-profound
hearing loss
Sponsor and 
Clinical Phase[COMPANY_001]
Phase 1/2
Investigation type Gene therapy
Study type Interventi onal
Purpose and 
rationaleThe current study  is to evaluate the safety , tolerability, and the potential 
ability of CGF166 delivered through IL-infusion to improve hearing and 
vestibular function. CGF166 is recombinant adenovirus 5 (Ad5) vector 
containing the human Atonal transcription factor (Hath1) cDNA
Primary 
Objective(s) and 
Key Secondary 
ObjectiveTo assess the safety and tolerability of  IL CGF166
To assess the efficacy of IL CGF166 as determined by [CONTACT_351967]To assess the efficacy of CGF166 as determined by [CONTACT_351968] (BAER) compared to
pretreatment values
To evaluate the effects of CGF166 on various assessments of
vestibular function compared to pretreatment values
To co mpare the changes in auditor y functions (speech recognition )
and vestibular functions before and after IL infusion of CGF166 into
the study ear
[COMPANY_001] Confidential Page 23
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Study design The current three part study utilizes an open label, single dose design for the 
investigation of CGF166 and will be conducted in multiple centers. Part A, B,
and C will be conducted in a sequential manner .
The current study will evaluate the safety, tolera bility, and potential efficacy  of 
CGF166 and the associated delivery procedures in patients with severe -to-
profound bilateral or unilateral hearing loss with intact vestibular function in 
the non-operative ear. Patients are required to have documented non-
fluctuating hearing loss.
Part A
Part A will include a safety and tolerability cohort (N=3). Patient dosing will be 
staggered; dosing the next patient in a cohort willbe based on a safety  data 
review including all data available through [ADDRESS_437795]-dose of the 
previously dosed patient(s) .
Part B
Part B will include a volumetric escalation design to evaluate infusion 
volumes of the same CGF166 concentration  in 3cohorts of 
patients (n=3 /cohort; total of 9patients).
Each subsequent cohor t will be dosed only after the volume delivered in the 
prior cohort is deemed to be safe and tolerable as determined by [CONTACT_351969] [ADDRESS_437796] -dose.
Safety review meetings will be organized to evaluate available safety  data 
and to determine if it is appropriate to escalate to the next infusion volume.
Part C
Based on the DSMB review of data from Part A and Part B of the study , Part 
C of the study will administer a dose volume of 30µL at the rate of 10 µL/min.
A total of 10 patients will be enrolled in Part C of the s tudy.
PopulationPatients with s evere -to-profound bilateral or unilateral hearing loss
with intact vestibular function in the non -operative ear
Adult patients who are candidates for a cochlear implant
Commercially 
Confidential 
Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Inclusion criteriaFor all Parts A, B and C of the study, male or female patients, [ADDRESS_437797] vestibular function in the non -
operative ear . Non -fluctuating severe -to-profound hearing loss is
required for t he study ear and is defined as:
Pure -tone average (PTA) within [ADDRESS_437798] 11 months p reviously
Word recognition within 20% of previous test at least 11 months
previously
Candidate ear (“study ear”): Minimal residual hearing based on the
pure tone average of 0.5, 1, 2, and 4 kHz thresholds of ≤110 dB HL .
Candidate ear (“study e ar”):pure tone audiometric thresholds of
≥50dBHLfor each testable octave frequenc yof0.125 and 0.250
kHz, ≥[ADDRESS_437799] frequency from 0.5 through
8kHz, and sentence recognition ≤50% at screening .
Patients with intact vestibular function in at least one ear (non -study
ear) as measured by  [CONTACT_351970] (VEMP)
MRI scan within 6 months or at screening to confirm su itability for
inner ear surger y
Ability to understand the study and provide informed consent;
willingness to comply with the protocol
Exclusion criteriaPatients with hearing loss caused by [INVESTIGATOR_18193]/developmental
disorders, e.g., cochlea aplasia or autoimmune ear disease
Patients with existing conductive hearing loss or mixed hearing loss
as judged by [CONTACT_351971] a thorough review of
all of the trial hearing assessments and MRI scan
Patients with cochlear implants or past cochlear implant in the
candidate study ear
Hearing loss due to any other cause that would not be expected to
respond to hair cell regeneration, for example trauma or central
auditory lesions or lack of an auditory nerve
Patients who will require ototoxic drugs as routine therapy over the
course of the study, such as cy stic fibrosis patients
Any contraindication to t he planned surger y or anesthesia as
determined by [CONTACT_11065], anesthesiologist, or designee
Previous surgery in the study ear
Any otological history, such as chronic otitis, cholesteatoma,
tympanic membrane perforation, that suggests poor candidac y for
cochlear implant or inner ear surgery or suggests potential
interference with study auditory or vestibular function tests
Pregnant women
Abnormal vital signs and/or ECG that suggest potential
contraindication for planned study anesthesia
Past serious advers e reaction to anesthesia
Meniere’s Disease
History of radiation therapy tothe head and neck
Participation in a clinical trial within the last 30 days
[COMPANY_001] Confidential Page 25
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Investigational and 
reference therapyCGF166 is recombinant adenovirus 5 (Ad5) vector containing the
human Atonal transcription factor (Hath1) cDNA. CGF166 will be
provided in a septum vial, containing 0.5 mL  of
opalescent liquid viral vector.
In Part A and Part B all investigational infusion volume was infused
at a rate of 10 µL/min ex cept 1 patient where in fusion volume was
infused at a rate of 20 µL/min. In Part C all following protocol
amendm ent 5 all investigational infusion volumes will be infused at a
rate of up to 10µL/min in to the perily mphatic space
Efficacy 
assessmentsAuditory assessments
Pure tone audiometry , including immittance testing
Speech audiometry
Brainstem auditor y evoked response evaluations (BAER)
Vestibular assessments
Head Impulse test
Safety 
assessmentsPhysical examination
Otoscopy
Neurological exam
FSH verification and Pregnancy test (serum at screening and urine
at subsequent visits)
Vitals and body measurements (height, weight, temperature, blood
pressure, and pulse rate)
ECG
Clinical laboratory tests (hematology, chemistry , and urinalysis)
MRI with gadolinium (within 3 months or per formed at screening)
Adverse events
Other assessments
Commercially Confidential Information
Commercially Confidential Information
Commercially 
Confidential 
Information
[COMPANY_001] Confidential Page 26
Amended Protocol Version v06 (C lean) Protocol No. CCGF166X2201
Data analysisTone thresholds will be analyzed for ea ch frequency tested
separately.
Pure tone audiometry air conduction threshold data will be listed and
graphically displayed by [CONTACT_4676], infusion volume, frequency, and
visit/time.
Summary  statistics will be provided by [CONTACT_351972], frequency,
ear and visit/time.
Change from baseline of the thresholds (mean of screening and
baseline visit) will also be summarized by [CONTACT_351972],
frequency, ear and visit/time
Key words Hearing loss, cochlear implant, gene therapy
[COMPANY_001] Confidential Page 27
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Assessment schedule
Study PhaseScreen ing 
visitBaseline Tre atm ent day End of  Study5
Day -63 to -4Day -3 to -1 Day 2Day 4 Day 6Day 15 Day 29 Day 57 Day 113 Day 169
Visit Numbers 1 2 4 5 6 7 8 9 11 13 / 777 777
Time (h) pre -infus ion Post-infus tion 4 hr
Inclusion/Exclusion x x
Relevan t medical 
history/Curre nt medical 
conditionsx x
Demography x
Audi tory and vestibular 
funct ion assessm entsx x x x
x x x
History of alco hol and 
drug dependenc ex x
Genera l Physical exam x x
Otos copy x x x x x x x x
Neurol ogical evaluation x x x x x x x x x x x
Pregna ncy te st x (serum ) x x6x
HIV and Hepatitis x
Vitals Signs  and body  
measure ments
Body Height x
Body Weight x x x x
x x
Body Temperature x x x x x x x x x x x
Blood pre ssu re / Pulse 
ratex x x xx x x x x x x
ECG x x x x x x x
Hematology, Blo od 
chemistry, Urinalys isx x x x x x x x xPost-op Obser vati on period Follow-up Period
as needed
1Day 1
3
5 - Pts. Who ha ve com pleted Day 169 in the study  will return to site as so on as possbile and complete end of study  vis it 777; Patients who have not completed Day [ADDRESS_437800] ete en d of  study (visit 777) assessm ent on Day 169
6 - as sessm ent done  if it  is end of study assessm ent.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 28
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Study P haseScreening 
visitBaseline Treatment day End of Study5
Day -63 to -4 Day -3 t o -1 Day 2Day 4Day 6 Day 15 Day 29 Day 57 Day 113 Day 169
Visit Numbers 1 2 4 5 6 7 8 9 11 13 / 777 777
MRI with gadolinium x x3x3x3x
C-SSRS x x x x x x
Com men ts
Adve rse events
Conc omitant 
med s/Therapi[INVESTIGATOR_351952] x6x
[ADDRESS_437801]-op Observ ation pe riod Follow-up Period
5 - Pts. Who ha ve completed Day 169 in th e study w ill return to s ite as soon a s possbile and com plete end of study vis it 777;  Patients who have  not c ompl eted  Day 169 
in the  study  will co mplete end of study  (visit 777)  assessmen t on D ay 169Day 1
3
as needed
as needed
as needed
x
x
C-SSRS- Columbia Su icide Severity Rating S cale;
3 MRI may be performed  if the  audiom etery meets one of the  stoppi[INVESTIGATOR_351953] 29
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
1 Introduction
1.1 Background
Sensorineural hearing loss and vestibular dy sfunction may result from destruction of inner ear 
sensory  hair cells and/or auditory  nerves. Humans are born with ~30,000 sensory  hair cells. 
Sensory  hair cells in the organ of Corti, located within the mammalian cochlea, are critical for 
auditory  function while vestibular sensory  hair cells located in the vestibular canals andthe 
utricle and saccule provide thebasis for vestibular function. Sensory  cells can be damaged or 
destroy ed by [CONTACT_351973] (chemotherap y and aminogl ycosides), loud noises, 
infections or simply  aging and loss of these cells is permanent as they do no regenerate. 
Hearing loss is currently treated with a hearing aid or a cochlear implant in patients with 
severe impairment; patients are eligible for a cochlear implant when they have severe to 
profound hearing loss with the inability  to discriminate 40% of speech. No pharmacologic 
agents exist to restore hearing function. More than 300,[ADDRESS_437802] received 
cochlear implants. Cochlear implants improve auditory  function but require invasive surgery , 
require ongoing maintenance and patient training; they also are expensive. Severe vestibular 
dysfunction pa tients may experience debilitating vertigo and nausea. There is no therapy  other 
than rehabilitation to acquire environmental signals to compensate for vestibular dysfunction. 
There are no therapeutic options available to regenerate sensory  hair cells to restore auditory 
or balance function and as such this represe nts a significant medical need.
The atonal gene, Atoh1, is a basic helix -loop-helix (bHLH) transcription factor that is required 
for initiation of the required gene regulatory  pathway  for differen
tiation of hair cells from 
progenitors during prenatal development. The ATOH1 protein is called Hath1 in humans  
 Moreover, ATOH1 expression can force the supporting cells, which 
normally  surround the sensory  hair cells and lack sensory function, to transdifferentia te into 
new sensory  hair cells.
1.1.1 Relevant data summa ry
CGF166 is a replication -incompetent Adenovirus 5 (Ad5) vector engineered to deliver Hath1 
expressed under the control of the GFAP (glial fibril lary acidic protein) promoter. CGF166 is 
provided as a solution in single -use septum vials that are stored frozen at -20°C and thawed 
prior to use.
Commercially Confidential InformationCommercially Confidential 
Information
[COMPANY_001] Confidential Page 30
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Pharmacology
The GFAP promoter will provide for low level expression restricted to supporting and 
neuronal cells.
CGF166 contains the GFAP promoter, which will limit the Hath1 transgene expression to 
cells that have endogenous GFAP protein expression. Studies by (Rio et al 2002) and 
(Schlecker et al 2011 )show endogenous GFAP protein expression by [CONTACT_351974]: cochlear supporting cells, organ of corti, vestibular supporting cells, 
and glial cells in the spi[INVESTIGATOR_351954]. Sensory  hair cells did not show positive GFAP staining. 
FAP protein positive cells 
included the supporting cells in the organ of Corti and in the macular organ ampulla as well as 
in the glial cells of the spi[INVESTIGATOR_351954]. Additionally , (Staecker et 
al 2011 )report a simila r 
distribution pattern obtained using an adenoviral vector expressing GFP under the control of 
the GFAP promoter. These studies taken together support that the GFAP promoter contained 
in CGF166 will limit expression of Hath1 to the supporting cells in the normal and injured ear.
The GFAP promoter was chosen for its selectivity to limit transgene expression to supporting 
cells and also for its ability  to promote the generation of sensory  hair cells. 
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 31
Amended Protocol Version v06 (Clean ) Protocol No. CCGF166X2201
CGF166 regenerates sensory hair cells in hu man vestibular explants ex vivo
Human vestibular explants, harvested from mature human vestibular end organs at the time of 
laby[CONTACT_351975] y, provide a unique opportunity  to study  gene transfer agents designed to treat 
inner ear disorders. CGF166 -mediated Hath1 expression has been shown to regenerate 
sensory  hair cells was evaluated in human macular organ cultures. These studies demonstrated 
that CGF166 mediated Hath1 expression effectively  regenerated sensory hair cells in human 
explants cultures compared with the n eomycin-treated control sample.
Commercially Confidential Information
[COMPANY_001] Confidential Page 32
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Development of IL delivery for inner ear expos ure
IL delivery  is the intended clinical route of admi nistration for inner ear gene delivery  of 
CGF166. This route of delivery  is expected to distribute the vector throughout the cochlea and 
vestibular fluid space to allow access to the target supporting cells in the organ of Corti and 
vestibular organs. Whil e IL delivery  was successfully  developed for clinical and non-clinical 
use, the point of access varied between species due to anatomical variations of the external 
auditory  canal (EAC), middle ear, and skull . The clinical access point is via the stapes 
footplate/oval window and will deliver CGF166 into the scala vestibuli perily mph. 
Also, human temporal bone studies were conducted to optimize the IL delivery  method via 
the stapes footplate for clinical studies (Investigator ’s Brochure ).
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 33
Amended Protocol Version v06 (Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 34
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 35
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 36
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 37
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
[IP_ADDRESS] Human pharmacokinetic data
Not applicable .
[IP_ADDRESS] Human pharmacody namic data
Not applicable .
1.2 Stud y purpose
The current study  is to evaluate the safety, tolerability , and the potential ability  of CGF166 
delivered through IL-infusion to improve hearing and vestibular function. CGF166 is 
recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor 
(Hath1) cDNA.
Commercially Confidential Information
[COMPANY_001] Confidential Page 38
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
2 Study  objecti ves
2.1 Primary  objective(s)
To assess the safet yand tolerability  of IL CGF166
To assess the efficacy  of IL CGF166 as determined by  [CONTACT_351976]
2.2 Secondary  objective(s)
To assess the efficacy  of CGF166 as determined by [CONTACT_351977] (BAER) compared to pretreatment values
To assess the efficacy  of CGF166 in regenerating vestibular function as determined by  [CONTACT_351978]
To compare the c hanges in auditory  functions (speech recognition )and vestibular
functions before and after IL infusion of CGF166 between the stud y ear
2.3 Exploratory  objective(s)
Commercially Confidential Information
[COMPANY_001] Confidential Page 39
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
[ADDRESS_437803] documented non-fluctuating severe- to-profound bilateral or unilateral hearing loss prior 
to enrollment . Amaximum of 22 patients will beenrolled in this 3 Part , 5cohort trial (Figure 
3-1).
[COMPANY_001] Confidential Page 40
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 41
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Part A
Part A will assess the safety  and tolerability  as well as potential efficacy  following a single IL 
dose of 20 uL of CGF166 concentration .Patient enrollment will be 
staggered so that a safet y data review can be done after each treated patient
(~4weeks aftertreatment) prior to dosing each subsequent patient .
Part B
Part B will include a volumetric escalation design to evaluate up to 3infusion volumes 
(between 20 and 60µL)of the same CGF166 concentration  in 3cohorts of 
patients (n=3/cohort; total of 9patients). All dose volumes are subject to change based on trial 
safet y data.
Each subsequent cohort will be dosed only after the volume 
delivered in the prior cohort is 
deemed to be safe and tolerable as determi ned by [CONTACT_351979] y Monitoring board (DSMB) . 
TheDSMB will consist of internal [COMPANY_001] personnel as well as at least one external subject 
matter expert who isnot serving as an investigator orotherwise privy  to trial data. 
Themembership and workings of the DSMB will be detailed in the DSMB Charter . 
Inaddition, the scheduling and dosing of the first patient in each cohort will be staggered to 
allow at least a four week interval in between treating the remaining 2 patients in each cohort .
Part C
Consid ering the preliminary  overall review of the data including changes observed in 
audiometry  for patients from Cohort 1 through Cohort 4, the DSMB endorsed the team’s 
proposal that 30 µL
 is the maximum tolerated dose (volume) observed in the study .
The highest safe and tolerable volume determined in Part B will be used for IL-infusion in 
Part C patients. A total of [ADDRESS_437804] 4week sof study assessments .
Part A -C
Patients will undergo the same protocol -required assessments and visit schedule in all Parts of 
the trial (A-C). Part C of the study  will only commence once preliminary  safety and 
tolerability  has been established for CGF166 and the associated delivery  methods in patients 
in Part A and B.
The trial duration will consist of 63day screening period followed by a 1-3 day baseline
assessment period and in house surgi
cal dose/post operation assessment period (~6-14days)
followed bya 6month post-dose assessment period. In addition ,alldosed patients in all 
Parts A-C will beadvise dof the opportunity to enroll in a separate protocol 
During the screening period, eligibility  of potential patients will be verified at the study  centers.
Commercially Confidential 
Information
Commercially Confidential Information
Commercially Confidential 
Information
[COMPANY_001] Confidential Page 42
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Potential patients will be evaluated for fitness to undergoing protocol -required surgery  and for 
the planned therap y based on physical exam, MRI , past/current medical history , and 
laboratory  testing. During the screening period, potential patients will also undergo 
pre-treatment , auditory and vestibular function tests.
At least two outpatient visits during the screening period are anticipated in order to complete 
the required verification and assessments. If all screening assessments can be completed in 
one visit, that is allowed. Additional outpatient screening visits (i.e.,more than 2 visits) are 
perm itted pending patients’ and clinic schedule and the need for re-verifica tions and potential 
re-testing.
Based on the screening assessments, one ear will be selected as the study  ear and will undergo 
the study  required surgery; criteria for the selection of the study  ear are described as follow:
The ear with more severe hearing loss as determined by  [CONTACT_351980]
If both ears have equal severity  in hearing loss, then the study  ear will be selected b y the
investigator’s preference
Upon completing the screening visits, eligible patients will be scheduled for a baseline visit 
and surgery .
Baseline (Day  -3 to -1)
Eligible patients will return to the study  center at baseline (Day  –3 to -1) and undergo 
pre-operative preparatio n as well as pre -treatment functional assessments.
Day 1 visit
On Day 1, study  patients will undergo the required protocol 
assessments and the stapedotomy 
for delivery  of the study  drug to the scala vestibul iperilymphatic space of the inner ear .At the 
completion of the surgery  and study  drug infusion, study  patients will recover in the surgical 
center’s post -op facility  and undergo post -surge ry evaluations and assessments. Study  patients 
may be transitioned to either the inpatient unit of the surgical center or pre -arranged 
temporary  housin g close to the surgical center.
Day [ADDRESS_437805] surger y days (Day  2 to Day 6) and will 
undergo the protocol -required safet y follow up evaluations. Study  patients will be discharged 
home if there are no significant adverse events requiring prolonged monitoring. Patients will 
have the option to remain in the provided housing until the completion of the Day  14 visit.
Subsequent visits will be scheduled with the stu dy patients prior to being discharged.
Commercially 
Confidential Information
[COMPANY_001] Confidential Page 43
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Day 15visit
Study  patients will return to the study  center to have surgical packing removed from their ear 
and will also undergo study  required assessments. Patients will be discharged home or to their 
local housing at the end of all study  required evaluations. Patients will be reminded of their 
next scheduled visit.
Follow  up and end of study  visits
Total follow -up period in the trial will be 6 months after administration of CGF166. The 
follow -up visit s will be at 2, 4, and 6month s/EOS . 
Patient who have already  completed Day 169 assessment (~ 6 month) will return to site to 
complete end of study  visit (visit 777) as soon as practicall y possible. Patients who have not 
completed Day  169 will complete end of study visit (visit 777) on Day  169.   
During each visit to the study  center, post-
operative recovery  of the study  ear will be 
monitored and evaluated. Study  patients will also undergo the study -required safety , 
auditory , and vestibular function tests during each visit. Bio-distribution blood samples 
will also be collected during each visit. Samples for immunogenicity  testing will be collected 
as per the blood log. At completion of the 6month post-surgery  visit (end of study  visit), if 
there are no significant adverse events requiring prolonged monitoring, study  patients will be 
considered to have completed the study  and will be discharge dfrom the study .
Detail on the pre-surgery  preparation, the surgical procedure, and the preparation of study 
drug as well as infusion procedure can be found in the study  surgical and pharmacy and drug 
delivery manual.
Detail on performing the study  auditory  and vestibular assessments can be found in the study 
auditory  and vestibular evaluation manual.
Safety Data Review s:
Prior to dosing each pati ent in Part A (cohort 1) and prior to dosing the 2 remaining patients in 
Part B (cohorts 2 -4), a review of all safety  and tolerability  data as well as a review of selected 
auditory  and vestibular function data will be conducted. Data considered for review will be 
those available up to [ADDRESS_437806] 4 weeks of study  
Commercially Confidential InformationCommercially 
Confidential Information
[COMPANY_001] Confidential Page 44
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
assessments . Safety  and tolerability  must be assessed as satisfactory  in order to proceed to the 
next cohort. This decision will be made by [CONTACT_4318] . Should notable adverse events or 
safet y concerns be found at one of the planned dose levels, the next planned dose level ma y be 
changed, as summarized in Section 5.5.5.
For Part C, the safet y review described above will be performed as each [ADDRESS_437807] 4 weeks of study assessments.
3.2 Rationale of study  design
The open label, adaptive gene therapy  trial design is intended to assess the safety , tolerabilit y 
and efficacy  of a single dose of CGF166. The trial design uses a staggered patient enrollment 
with continuous data reviews to limit as much unforeseen risk as possible prior to enrolling 
each patient in Part A or initiating another cohort in Part B , while also allowing for a potential 
clinical benefit. In addition, t he trial design uses a sequential three Part design (Part A -Safety ; 
Part B -Volume escalation; Part C -Efficacy )with cohort safet y data reviews as described
above .Based on the preliminary  review of the data including changes observed in audiometry 
for patients from Cohort 1 through Cohort 4, the DSMB endorsed the team’s proposal that 30 
µL is the maximum tolerated dose (volume) and start the Part C of the st udy.
3.3 Rationale of dose/regimen, duration of treatment
As a gene therapy  that requires surgical administration, this will be a single dose study  to 
assess the safety  and tolerability  as well as efficacy  of CGF166.
Commercially Confidential Information
[COMPANY_001] Confidential Page 45
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
3.4 Rationale for choice of comparator
Not applicable .
3.5 Purpose and timing of interim analy ses/design adaptations
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 46
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
3.[ADDRESS_437808] be excluded from this study . Some of 
thevestibular assessments may  provoke nausea, vomiting and disequilibrium; these s ymptoms 
should be antic ipated and managed expectantl y.
3.6.[ADDRESS_437809] for 
a longer period of time.  Strategies to avoid patient Valsalva maneuvers and possible effects 
on the stapedotomy  plug or the re-positioned tympanic membrane are important . 
Such preemptive approaches might include treatment with dexamethasone and anti -histamines, 
for example.
Known surgical risks of mild to moderate severity  include persistent alteration of taste due to 
injury  of the chorda tympani, infectious otitis media, perily mph fistula, reparative granuloma 
and perforation of the tympanic membrane, and worsened hearing. Each of the foregoing 
items carries a riskof 5% or less. Rare, but more serious adverse effects include facial nerve 
palsy , infective laby[CONTACT_351981].
3.6.3 Risks of administering volume and CGF166 into the inner ear
Commercially Confidential Informationv
[COMPANY_001] Confidential Page 47
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
3.6.[ADDRESS_437810]-operative improvement in their 
air-bone gap, so for those patients with tinnitus, it’s possible that CGF166 therapy  could 
improve the severity  of their tinnitus too.
For more details please refer to the Investigator Brochure .
[ADDRESS_437811] ensure that all patients being considered for the study  meet the 
following eligibility  criteria. No additional criteria should be applied by [CONTACT_093], in 
order that the stud y population will be representative of all eligible patients.
Patient selection is to be established by [CONTACT_233626]/exclusion criteria at 
screening and baseline. A relevant record (e.g.,checklist) of the eligibility  criteria must be 
stored with the source documentation at the stud y site.
Deviation from anyentry  criterion excludes a patient from enrollment into the study .
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 48
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
4.[ADDRESS_437812] to fulfill allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2.For all Parts (A, B and C) of the stud y, male or female patients, [ADDRESS_437813] vestibular
function. Non- fluctuating severe -to-profound hearing loss is required for t he study  ear and
is defined as:
PTA within [ADDRESS_437814] 11 months previously .
Word recognition within 20% of previous test at least 11 months previously
[AAO -HNS Hearing Classification Sy stem]
3.Candidate ear (“stud y ear”): Minimal residual hearing based on the pure tone average of
0.5, 1, 2, a nd 4 kHz thresholds of ≤110 dB HL
4.Candidate ear (“stud y ear”): Pure tone audiometric thresholds of ≥[ADDRESS_437815] frequenc y
of 0.125 and 0.250 kHz, ≥ [ADDRESS_437816]
frequency  from 0.5 through 8 kHz and sentence recognition sco res ≤50% at screening .
Subject responses will be monitored for vibrotactile sensation, particularl y for the low -
frequency  stimuli (e. g., 125 and 250 Hz). A frequency  that elicits vibrotactile responses at
levels below 70 dB HL will be considered “not testable” for hearing threshold and only
those frequencies that are testable for hearing threshold will be considered for patient
inclusion/exclusion in the study .
5.Patients with intact vestibular function in at least one ear (non -study  ear) as measured by
[CONTACT_351982] m yogenic potential (VEMP)
6.Able to communicate well with the investigator, to understand and comply with the
requirements of the study
7.Meet surgical requirements/eligibility (including MRI  scan within 3 months or at
screening to confirm suitability  for inner ear surgery )
8.Patients must weigh at least [ADDRESS_437817] a body  mass
index (BMI) <45 kg/m2. BMI = Bod y weight (kg) / [Height (m)]2
4.2 Exclusion criteria
Patients fulfilling anyof the following criteria are not eligible for inclusion in this study :
1.
Use of other investigational drugs at the time of enrollment, or within [ADDRESS_437818] has returned to baseline, whichever is longer;
or longer if required b y local regulations.
2.History  of hypersensitivity  to any  of the study  drugs or to drugs of similar chemical
classes.
3.Patients with hearing loss caused by  [INVESTIGATOR_18193]/developmental disorders, e.g. ,cochlea aplasia .
4.Patients with existing condu ctive hearing loss or mixed hearing loss as judged b y the
Principal Investigator [CONTACT_43638] a thorough review of all of the trial hearing assessments ,
air-bone gap assessment based on air and bone pure tone audiometry  and MRI  scan .
5.Patients with a history  of cochlear implant in the study  ear.
[COMPANY_001] Confidential Page 49
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
6.Hearing loss due to an y other cause that would not be expected to respond to hair cell
regeneration, for example trauma or central auditory  lesions or lack of an auditory  nerve
7.Patients who will require ototoxic drugs a s routine therapy  over the course of the study ,
for example cystic fibrosis patients .
8.Any contraindication to the planned surgery  or anesthesia as determined by  [CONTACT_11065],
anesthesiologist, or designee .
9.Women of child-bearing potential, defined as all wo men phy siologically  capable of
becoming pregnant, unless they are using highly  effective methods of contraception
during dosing and for 6 months following treatment period of the investigational
medication. Highly effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation
methods) and withdrawal are not acceptable methods of contraception .
Female steriliz ation (have had surgical bilateral oophorectom y with or without
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. In
case of oophorectomy  alone, only  when the reproductive status of the woman has
been confirmed b y follow up hormone level assessment .
Male sterilization (at least 6 months prior to screening). For female subjects on the
study  the vasectomized male partner should be the sole partner for that subject .
Combination of any  two of the following (a+b or a+c, or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception or other
forms of hormonal contraception that have comparable efficacy  (failure rate <1%),
for example hormone vaginal ring or transdermal hormone contraception .
b. Placement of an intrauteri ne device (IUD) or intrauterine s ystem (IUS) .
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm or
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository .
In case of use of oral contraception women should have been stabile on the same pi[INVESTIGATOR_5311] a minimum of [ADDRESS_437819] attempt for cochlear implant in the study  ear or any
other inner ear surg ery that could interfere with drug efficacy.
12.Any other otologic history , including but not limited to chronic otitis, cholesteatoma,
tympanic membrane perforation
, head and neck radiation or Meniere’s disease, that
suggests poor candidacy  for cochlear impl ant or inner ear surgery  or suggests potential
interference with study  auditory  or vestibular function tests.
13.Abnormal vital signs and/or ECG that suggest potential contraindication for planned stud y
anesthesia or past serious adverse reaction to anesthesi a.
14. Patients with estimated glomerular filtration rate (GFR) < 30 ml/min (MDRD formula) at
screening .
15.Patients with heart failure NYHA class III or IV .
[COMPANY_001] Confidential Page 50
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
16.Patients with Child -Pugh clas s C cirrhosis .
17.History  of m yocardial infarction, coronary  by[CONTACT_4897] , orany percutaneous coronary
intervention (PCI) within 6 months prior to screening.
18.Patients who require chronic anticoagulation, except daily  aspi[INVESTIGATOR_248] .
19.A psy chiatric disease or substance abuse history  likely  to interfere with protocol
compliance .
20.Any medical condition, judged b y the investigator, that is likely  to interfere with the
patient’s participation in the study , or likely  to cause serious adverse events during the study .
21.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female
after conception and until the termination of gestation, confirmed by  a positive hCG
laboratory  test.
22. Immunocompromised patients, as judged by  [CONTACT_351983] ,
physical exam and CBC
No additional exclusions may be appli ed by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
5 Treatment
5.1 Protocol requested treatment
5.1.1 Investigational treatment
CGF166 isarecombinant 
adenovirus 5 (Ad5) vector containing the human Atonal 
transcription factor (Hath1) cDNA. 
CGF166 will be delivered using aninfusion pump system with ablunt needle cannula 
(asperthe Surg ical and Pharmacy /Drug Delivery Manual sdetails provided separately ).
5.1.[ADDRESS_437820] been 
completed; dose volumes administered reflect the study  treatment for each cohort including 
planned dose volume for Part C of the study  (see Table 5-1for estimated viral particle 
delivery  quantit y and normalized doses estimates) .
Commercially Confidential InformationCommercially Confidential Information
[COMPANY_001] Confidential Page 51
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Study  treatments are defined as:
Part A:
Cohort 1: single dose of 20 µL  CGF166
Part B:
Cohort 2: single dose of 40 or 30 µL CGF166
Cohort 3: single dose of 40 µL  CGF166
Cohort 4
: single dose of 60 µL  CGF166
Part C:
Cohort 
5: single dose of 30 µL  @ 10 µL /minCGF166
5.3 Treatment assignment
Treatment numbers will be assigned in ascending, sequential order to eligible patients 
(seeSection 5.5.1 for details). The investigator will enter the Treatment number on the CRF.
5.4 Treatment blinding
This is an open label trial.
5.5 Treating the patient
5.5.1 Treatment /Patient numbering
Screening number
Each patient screened is assigned a unique screening number. The screening number is a 
combination of the center number, that is provided by [CONTACT_5343], and a three digit number 
starting with 001 for each patient which is assigned by [CONTACT_737]. Theref ore, if the 
center number is 1 (any leading 0’s in the center number are dropped) the screening numbers 
will be assigned such as 1001001, 1 001002, 1 001003 in ascending order. If the center number 
is 2(or0002), the screening numbers will be 1002001, 100 2002, 1002003 in an ascending 
order.
Commercially Confidential Information
[COMPANY_001] Confidential Page 52
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Treatment number
If the patient is deemed eligible for the study  and will commence dosing, a treatment number 
will be assigned. Once assigned to a patient, a treatment number will not be reused.
The treatment number becom es the definitive patient number as soon as a patient receives the 
first dose of the respective study  treatment.
There should be a source document maintained at the site which links the screening number to the 
treatment assignment number (once assigned). This source document should be provided to all 
appropriate parties (i.e. ,Central Laboratory , ECG Laboratory ) as soon as this is available.
5.5.2 Dispensing the study treatment
The investigational drug, CGF166 will be prepared by [CONTACT_351984].
For preparation of the study  medication, please refer to the separate Pharmacy /Drug Delivery
manual.
Appropriate documentation of the patient specific dispensing process must be maintained.
The medication labels will be in the local language, will comply  with the legal requirements of each 
country , and will include storage conditions for the drug but no information about the patient.
5.5.3 Handling of study  treatment
[IP_ADDRESS] Handling of investigational treatment
Investigational treatment must be received at the study  site by a designated person, handled 
and stored safel y and properl y, and kept in a secured locatio n to which only the Investigator 
and designated staff have access. Upon receipt, the study  drugs should be stored according to 
the instructions specified on the labels and in the Pharmacy /Drug Deliver yManual provided 
separately .
Commercially Confidential Information
[COMPANY_001] Confidential Page 53
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Storage conditions must beadequatel y monitored and appropriate temperature/humidity  logs 
maintained as Source data.
The Investigator must maintain an accurate record of the shipment and dispensing of study 
drug in a drug accountability  ledger. Drug accountability  will be noted by [CONTACT_351985] g 
site visits and/or at the completion of the trial.
All drug supplies are to be used only for this protocol and not for any other purpose. 
Unless specifically  instructed by [CONTACT_5343], the Investigator must not destroy any drug labels, 
or any partl y used or unused drug supply.
At the conclusion of the study , and, if allowed during the course of the study  (e.g.,an open 
label study ), the I nvestigator will provide a copy  of the drug accountability  ledger to the Monitor.
Only  after receiving a written authorization by [CONTACT_5343], the Investigator/designee will send 
all the unused and partly used drug supplies as well as the empty  containers to the address 
provided at the time of authorization for destruction or have the unused and partly  used drug
supplies as well as the empty  containers destro yed by [CONTACT_779]’s pharmacist, providing a drug 
destruction certificate.
[IP_ADDRESS] Handling of other study treatment
Not applicable.
5.5.[ADDRESS_437821] CRF including an y observed leaking from the ear canal during dosing.
5.5.5 Permitted dose adjustments and interruptions of study  treatment
Study  drug dose adjustments and/or interruptions are not permitted, unless during surgical 
procedure the surgeon deems the patient ineligible or is unable to dose the patient.
In case of notable adverse events and safet y concerns during dose escalation of the study , the 
following changes to the next planne d dose level may  be considered:
Administration of a dose below the starting dose
Administration of an intermediate dose between the current and preceding dose
Administration of an intermediate dose between the current and next planned dose
Repeated adminis tration of the current dose
Termination of an y further dose escalation
These changes must be recorded on the Dosage Administration Record CRF.
5.5.[ADDRESS_437822] be recorded on the Concomitant medications/Significant 
non-drug therapi[INVESTIGATOR_50061].
5.5.7 Rescue medication
Not applicable .
[COMPANY_001] Confidential Page 54
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
5.5.8 Concomitant treatment
All prescription medications, over-the-counter drugs and significant non-drug therapi[INVESTIGATOR_014] 
(including physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant medications/ Significant non -drug therapi[INVESTIGATOR_50062].
Medication entries should be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontin uation date and the reason for therap y.
5.5.9 Prohibited treatment
Use of known ototoxins , for example systemic aminogly coside antibiotics, should be avoided 
if possible following dose administration through study  completions. If a known, potent 
ototoxin should be required, for example cisplatin, then the patient may remain in the study 
but should be excluded from the efficacy  anal ysis.
5.5.10 Discontinuation of study treatment and premature patient withdrawal
Study and cohort “Stoppi[INVESTIGATOR_004]”
The study  will be put on h old and no new patients dosed pending a full safety  review if any  of 
the following criteria should be met:
3 or more patients with study drug-related or surgical procedure -related SAEs are reported
At least 2 patients in the same cohort experience a simila r AE which is assessed as severe
in intensity , and is related to the study drug or surgical procedure
Clinical evidence of post -operative vestibular d ysfunction of moderate severity  (impairs
instrumental activities of daily  living, such as preparing meals or housework) that persists
longer than 4 weeks in 2 patients.

1 patient develops a sever e systemic immune response attributed to study  drug
1 patient develops a severe infection consistent with those caused b y adenovirus
(ifconfirmed to be relate dto study  drug).
Commercially Confidential Information
[COMPANY_001] Confidential Page 55
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Individual patient w ithdrawal
Patients may voluntaril y withdraw from the study  for any reason at any time. They  may be 
considered withdrawn if they  state an intention to withdraw, fail to return for visits, or become 
lost to follow -up for an y other reason.
If a patient withdrawal occurs for any reason, the investigator must make every  effort to 
determine the primary  reason for a patient’s withdrawal from the study  and record this 
information on the CRF.
The investigator should withdraw the patient from study  if, on balance, he/she believes that 
continuation would be detrimental tothe patient’s well-being. Apatient may withdraw
consent from the stud yat any  time.
A decision to not administer thesingle dose study treatment and patient withdrawal will be at 
the discretion of the Investigator, under the following circumstances:
Complication during surgery  or patient ear anatomy  does not allow the surgeon to 
properl y administer the dose infusion
Use of prohibited treatment
Any other protocol deviation that results in a significa nt risk to the patient’s safety
Patients who discontinue study  treatment should NOT automatically  be considered withdrawn 
from the study . As single dose gene therapy , every  effort will be to follow up with all treated 
patients whom have discontinued for whatever reason. See Section [ADDRESS_437823] to follow -up (i.e. ,those patients whose status is unclear because they 
fail to appear for study  visits without stating an intention to withdraw), the investigator should 
show “due diligence ”by [CONTACT_187888], e.g. , dates of telephone calls, registered letters, etc.
Patients who are withdrawn from the study  for reasons other than safet y or lack of efficac y 
will not be replaced b y an equal number of newl y enrolled patients.
5.5.[ADDRESS_437824]:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_351986] -up.
[COMPANY_001] Confidential Page 56
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
All efforts should be made tocomplete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table .
[COMPANY_001] will continue to keep and use collected study  information (including any data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law.
All biological samples not yet analyzed at the time of withdrawal may  still be used for furthe r 
testing/anal ysis in accordance with the terms of this protocol and of the informed consent 
form.
5.5.[ADDRESS_437825] refer them for appropriate ongoing care.
All patients will be expected to participate in a separate long term follow -up observational study .
5.5.13 Early  study termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary , 
the patient should be seen as soon as possible and treated as a prematurel y withdrawn patient. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient’s interests. The investigator 
will be responsible for informing IRBs and/or ECs of the early  termination of the trial.
6 Visit assessments
The full Assessment schedule is presented at the end of the sy noptic section, above.
Patients should be seen for all visits on the designated day  or as close to it as possible.
Patients who discontinue study  before completing the study, and those who prematurel y 
withdraw from the study  for any reason, should be scheduled for a visit as soon as possible, at 
which time all of the assessments listed for the final visit will be performed.
Acceptable deviations ranges from assessment times based on logistical and operational 
considerations are detailed in separate data management module documents.
[COMPANY_001] Confidential Page 57
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
6.1 Dietary , fluid and other restrictions
During recruitment, screening/informed consent review, and baseline visit, the patients will be 
informed and reminded of the following restrictions:
Avoid strenuous phy sical exercise (e.g., weight training, aerobics, football) before each
visit anduntil after Study Completion evaluation.
Avoid alcohol for 48 hours before each visit until after Study  Completion evaluation.
Patients should avoid getting water into their ex ternal auditory  canal for 2 weeks after
surgery .
Patients may  not swim for 4 weeks after surgery .
Patients may  not be passengers in airplanes for [ADDRESS_437826] 4 hours thereafter.
6.2 Patient demographics /other baseline characteristics
Patient demographic and baseline characteristic data to be collected on all patients include: 
date of birth, age, sex, race, predominant ethnicity.
Relevant medical history /current medical conditions data includes data until signature [CONTACT_86220]. Where possible, diagnoses and not sy mptoms will be recorded.
6.3 Treatment exposure and compliance
Not required.
6.4 Efficacy  assessments
Efficacy /Pharmacod ynamics will be measured in this clinical study  by [CONTACT_351987]:
Auditory assessments
Pure tone audiometry
Speech audiometry
Brainstem auditory  evoked response evaluations (BAER)
Vestibular assessments
Head Impulse Test
Commercially Confidential Information
[COMPANY_001] Confidential Page 58
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
6.4.1 Auditory assessments
[IP_ADDRESS] Pure tone audiometry
Hearing sensitivity  to frequency -specific pure tone stimuli will be determined by [CONTACT_351988] (air conduction) and bone- conduction vibrator 
(bone conducti on) using a standard loudness bracketing procedure. The patient will be asked 
to respond when s/he hears the tone, and the softest sound detected will be defined as 
threshold for that tone. Immittance testing is completed as part of standard audiometric 
assessment.
Air conduction thresholds will be measured for standard -frequency  and extended -
frequency  ranges: 0.125, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12.5, 14, 16 kHz.
Bone conduction will be measured for frequencies 0.25 - 4 kHz . Masking to determine
ear-specific bone conduction thresholds will be performed when necessary .
[IP_ADDRESS] Speech audiometry
For all speech perception tests, the patient repeats the words and/or sentences after they are 
presented. Speech perception is scored in percent of words correctly  repeated .
Ear-specific speech recognition threshold (SRT) will be measured using two -syllable
spondee words via monitored live voice through headphones. SRT is defined as the lowest
stimulation level at which speech perception is 50% correct .
Ear-specific word 
recognition at 40 dB sensation level (SL), or maximum comfortable
level if 40 dB SL not possible, will be tested using NU-6 words via monitored live voice
through headphones.
Aided word recognition testing for individual ears using consonant -nucleus -consonant
(CNC) words (Peterson and Lehiste 1962) will be presented at [ADDRESS_437827]
of 50monosy llabic words.
[IP_ADDRESS] AzBio Sentence test
The Minimum Speech Test Battery  (MSTB) for cochlear implant evaluation was updated in 
[ADDRESS_437828] 
(Spahr and Dorman 2004 ), due to ceiling effects in performance observed with the Hearing in 
Noise Test (Gifford et al 2008). The AzBio Sentences Test consists of [ADDRESS_437829]-A, both in quiet and with background 
10-talker speech babble noise presented at + 5 dB signal -to-noise -ratio (SNR). Presentation is
in the soundfield in an individual- ear aided condition .
[IP_ADDRESS] Hearing -in-Noise -Test (HINT)
The Hearing in Noise Test (HINT) (Nilsson et al 1994) consists of [ADDRESS_437830]-A in quiet and in speech-weighted noise at +[ADDRESS_437831] batter y 
[COMPANY_001] Confidential Page 59
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
has recentl y been updated to replace the HINT with the AzBio Sentences Test. However, the 
HINT can also be administered adaptivel y, with the sentences remaining at a fixed stimulation 
level and the noise level adapted until the patient scores 50% correct understanding. 
Performance is quantified as signal -to-noise ratio (SNR) in dB. This adaptive testing method 
avoids ceiling effects observed when using fixed stimulation levels; however, this method is 
not routinely  used clinically  in the US. One potential future benefit is it resembles adaptive 
sentence in noise testing in other languages, such as the German Oldenburger 
Satztest/Oldenburg Sentence Test (OLSA). Presentation is in the sound field in an individual -
ear aided condition.
[IP_ADDRESS] Brainstem auditory  evoked response evaluations (BA ER)
The BAER provides electroph ysiologic information on the status of the auditory  pathwa y 
from the periphery  up through the brainstem. The BAER waveform reflects responses from 
different neural generators, with the most robust neural response arising from the inferior 
colliculus, observed as wave V. The BAER can be elicited by [CONTACT_351989]-burst stimuli, the 
latter providing more frequency -specific information.
Surface electrodes are placed as non-inverting on the vertex, inverting on lobe or mastoid of 
the test ear, and ground on the forehead. The patient is at rest, and the click or toneburst 
stimuli are presented through insert earphones at a high level (starting level depends on degree 
of hearing loss), and the stimulation level is decreased until BAER threshold is obtai ned, 
defined as the lowest stimulation level at which a repeatable wave V is observed.
6.4.2 Vestibular assessments
[IP_ADDRESS] Head Impulse Testing
The head impulse test (HIT) is a clinical maneuver used to assess the vestibulo -ocular reflex  
(VOR) during quick head rotations. The examiner delivers small -amplitude (<20 degree) head 
rotations with high peak velocities in the planes corresponding to each of the six semicircular 
canals. (Halmagy i and Curthoy s 1988 , Cremer 1 998 ). A normal VOR results in a smooth eye 
movement equal and opposite direction to the head movement, thus achieving gaze 
stabilization without the need of a compensatory  eye saccade. A patient with a deficient VOR 
fails to keep his/her eyes on target and subsequently  makes a corrective, quick eye movement 
(a corrective/catch- up saccade) to refixate the target. When this refixation saccade occurs after 
the head has come to rest at the end of the head movement, it is visible to anexaminer and 
serves as an indicator of hypofunctional sensation in the semicircular canal predominantl y 
excited by [CONTACT_351990]. Head impulses can be directed in each of 6 directions, thereb y 
selectivel y testing the function of each of the 3 semicircul ar canals in each of the two 
laby[CONTACT_351991]. 
Over time, a patient with a hypofunctional semicircular canal may develop an ability  to make 
corrective saccades that begin and end during the head rotation. While this improves the 
patient ’s ability  to maintain visual fixation of a target during head movements, it also 
degrades the examiner’s ability  to detect hy pofunction of the semicircular canal. In such cases, 
a video Head Impulse Test (vHIT) is useful to identify  VOR abnormalities that are not 
obvious to the e xaminer. A vHI T system comprises an ey e-tracking camera and motion sensor 
[COMPANY_001] Confidential Page 60
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
mounted on light, securely  fit, head -worn goggles. Because the vHIT system’s camera travels 
with the head, it is less susceptible to missing corrective saccades that occur during thehead 
movement. Because the vHIT quantitatively  measures head and eye angular velocities 
throughout a head movement, it provides a numerical estimation of VOR gain, which is 
calculated as the ratio of slow phase (VOR -driven) eye velocit y divided by [CONTACT_351992].  
The vHIT has been well validated against the magnetic field scleral search coil technique, 
which is the gold standard for HIT measurements ( MacDougall et al 2013, 
Agrawal et
al2013). 
Commercially Confidential Information
[COMPANY_001] Confidential Page 61
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
6.5 Safet y
6.5.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological. If indicated based on medical history  and/or sy mptoms, 
rectal, external genitalia, breast, and/or pelvic exams may  be performed.
Information for all phy sical ex aminations must be included in the source documentation at the 
study  site and will not be recorded the CRF. Significant findings that are present prior to 
informed consent are included in the Relevant Medical History  CRF. Significant findings 
observed after informed consent signature [CONTACT_352004] y recorded on the Adverse Event CRF.
6.5.2 Vital signs
Vital signs include blood pressure (BP) and pulse measurements. After the patient has been 
sitting for 3 minutes, with back supported and both feet placed on the floor, systolic and 
diastolic BP will be measured using an automated validated device, with an appropriatel y 
sized cuff. In case the cuff sizes available are not large enough for the patient’ s arm 
circumfer ence, a sph ygmomanometer with an appropriatel y sized cuff may be used.
If vital signs are out-of-range at screening and baseline, the Investigator may obtain two 
additional readings ,so that a total of up to three consecutive assessments are made, with the 
patient seated quietl y for approximately  five minutes preceding each repeat assessment.
6.5.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured.
Body mass index (BMI) will be calculated using the following formula:
BMI = Bod y weight (kg) / [Height (m)]2
6.5.4 Laboratory  evaluations
In the case where a laboratory  assessment that is listed in the inclusion/exclusion criteria is 
outside of a protocol -specified range at screening and/or at the initial baseline, the 
assessment may be repeated once prior to randomization. If the repeat value remains outside 
of protocol -specified ranges, the patient is excluded from the study .
In the case where a laboratory  range is not specified by [CONTACT_760] , but is outside the 
reference range for the laboratory  at screening and/or initial baseline, a decision regarding 
whether the result is of clinical significance or not shall be made by [CONTACT_351993], in part, upon the nature and degree of the observed abnormality . The assessment 
may be repeated once prior to randomization.
Further retests at screening or baseline could be permitted if deemed necessary  by [CONTACT_1275]; however, each case must be discussed and agreed with the Sponsor on a case -by-
case basis.
[COMPANY_001] Confidential Page 62
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
In all cases, the Investigator must document in the source documents, the clinical 
considerations (i.e., result was/was not clinically  significant and/or medically  relevant) in 
allowing or disallowing the patient to continue in the study .
Clinically  relevant deviations of laboratory  test results occurring during or at completion of 
the study  must be reported and discussed with [COMPANY_001] personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. In ca se of doubt, [COMPANY_001] personnel should again be contact[INVESTIGATOR_530].
[IP_ADDRESS] Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(e.g., neutrophils, basophils, eosinophils, monocy tes, lymphocy tes) and platelet count will be 
meas ured.
[IP_ADDRESS] Clinical chemistry
Albumin, alkaline phosphatase, total bilirubin, bicarbonate/CO 2, calcium, cholesterol, chloride, 
creatinine, CK, -GT, glucose, LDH, inorganic phosphorus, lipase, amylase, magnesium, 
potassium, total protein, AST, ALT, sodium, triglycerides, BUN , and uric acid (for all 
laboratory  assessment s). Anti- Nuclear Antibody (ANA), anti-neutrophil cytoplasmic 
antibody  (ANCA ), rheumatoid factor, and anti-cyclic citrullinated peptide s will be measured 
at screening onl y.
If the total bilirubin concentration is increased above 1.[ADDRESS_437832] reacting bilirubin should be differentiated.
[IP_ADDRESS] Urinaly sis
A midstream urine sample (approx. 30 mL) will be obtained, in order to avoid contamination 
with epi[INVESTIGATOR_107183], and allow proper assessments.
A semi -quantitative “dipstick” evaluation for the following parameters will be performed: 
specific gravity , pH, glucose, protein, bilirubin, ketones, nitrite, leukocy tes and blood.
If the dipstick result is positive for protein, nitrite, leucocy tes and/or blood, the sample will be 
sent for microscopic analysis of WBC, RBC and casts.
[IP_ADDRESS] Special clinical laboratory  evaluations
Not applicable .
[COMPANY_001] Confidential Page 63
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
6.5.5 Electrocardiogram (ECG)
A standard [ADDRESS_437833] be made 
by a  qualified physician and documented on the ECG / in the ECG section of the CRF. 
Each ECG tracing should be labeled with the
study  number
patient / patient initials
patient / patient number
date
and kept in the source documents at the study  site. Clinically  significant abnormalities should 
be recorded on the relevant medical history /Current medical conditions CRF page prior to 
informed consent signature [CONTACT_275438]. Clinically  significant 
findings must be discussed with the sponsor.
The CRF will contain:
date and time of ECG
heart rate
PR interval
QT interval 
QTcF
QRS duration
Original ECG tracings, appropriatel y signed, will be archived at stud y site.
6.5.6 Hearing and balance assessments
The assessments for efficacy  outlined in Section 6.4 will also serve as safety  assessments.
6.5.7 Magnetic resonance Imaging (MRI)
Magnetic resonance imaging with gadolinium (MRI ) will be used to assess the structural 
integrit y of the inner to determine if the patients study  ear is suitable for enrolling the trial as 
well asfollowing treatment to assess the inner ear structura l integrit yand evaluate for other 
potential complications of treatment, including laby[CONTACT_351994] . The imaging 
acquisition will follow the local facility  procedures indicating the specific hardware and 
software settings for acquisition of all i nner ear structural parameters.
6.6 Pharmacokinetic assessments
Not applicable .
6.7 Other assessments
Not applicable .
[COMPANY_001] Confidential Page 64
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 65
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
7 Safety  monitoring
7.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product. Pre-existing medical conditions/diseases (i.e.,Medical 
History (ies)) are considered AEs if they worsen after providing written informed consent. 
Abnormal laboratory  values or test results constitute AEs only if they induce clinical signs or 
symptoms, or are considered clinicall y significant, or they  require therapy .
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by [CONTACT_351995], laboratory  test, or 
other assessments.
Commercially Confidential Information
[COMPANY_001] Confidential Page 66
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Adverse events must be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  [CONTACT_351996]:
1.the severit y grade:
mild:usually  transient in nature and generall y not interfering with normal activities
moderate: sufficientl y discomforting to interfere with normal activities
severe: prevents normal activities
2.its relationship to study  treatm ent
3.its duration (e.g., start and end date)
4.whether it constitutes a serious adverse event (SAE)
5.action taken regarding study treatment
6.whether other medication or therapi[INVESTIGATOR_95254] (concomitant medication /
non-drug therap y)
7.its outcome
An SAE is defined as any AE which meets an y one of the following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent form
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2.
All adverse events should be treated appropriately . Treatment may include one or more of the 
following: no action taken (i.e.,further observation only); study  drug dosage 
adjusted/temporaril y interrupted; study  drug permanently  discontinued due to this adverse 
event; concomitant medication given; non- drug therapy  given. The action taken to treat the 
adverse event should be recorded on the Adverse Event CRF.
[COMPANY_001] Confidential Page 67
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequentl y, if 
necessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions req uired to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications. This information will be included in the informed consent 
and should be discussed with the patient during the study  as needed.
7.2 Serious adverse event reporting
Screen Failures
Note the following requirement for Screen Failures: SAEs occurring after the subject has 
provided informed consent until the time the subject is deemed a Screen Failure must be 
reported to [COMPANY_001]. 
Treated subjects
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 30 days after the patient has stopped study  participation 
(defined as time of last dose of study  drug taken or last visit whichever is the later) must be 
reported to [COMPANY_001] within [ADDRESS_437834] be 
submitted within 24 hours of the investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new event.
Information about all SAEs (either initial or follow-up information) is collected and recorded 
on the Serious Adverse Event Report Form. The investigator must assess the relationship of 
any SAE to each specific component of the study  treatment (if the study  treatment consists of 
several components) , complete the SAE Report Form in English, and send the completed, 
signed form by [CONTACT_87109] 24 hours of the awareness of the SAE to the local CMO & PS
Department and also a copy  to the [COMPANY_001] Medical Expert [INVESTIGATOR_1238]/or Clinical Trial Leader 
(according to page 2 ). The telephone and fax numbers of the contact [CONTACT_351997] y and Epi[INVESTIGATOR_351955], specific to the site, are listed on page 2of this protocol 
and/or in the investigator folder provided to each site. The original copy of the SAE Report 
[COMPANY_001] Confidential Page 68
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Form and the fax confirmation sheet must be kept with the case report form documentation at 
the study  site.Follow -up information should be provided using a new paper SAE Report 
Form stating that this is a follow- up to a previously  reported SAE.
Follow -up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the 
patient continued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the investigational treatment a Drug Safet y 
and Epi[INVESTIGATOR_351956] y require further information from the 
investi gator for Health Authority  reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same 
investigational treatment that this SAE has been reported. Suspected Unexpected Serious 
Adver se Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities,
relevant ethics committees and additional regulatory  bodies as required for Gene Therap y 
studies (e.g the NIHin the [LOCATION_002]) in accordance with Directive 2001/20/EC or as per 
national regulatory  requirements in participating countries.
7.3 Liver safety  monitoring
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Liver events are divided into two categories:
Liver events of special interest (AESI) which consist of LFTs elevations
Medicall y significant liver events which are considered as serious adverse e vents (SAEs) 
and which consist of marked elevations of LFTs and / or pre -specified adverse events.
Please refer to Table 15 -1-Appendix 3 for complete definitions of liver events.
Any liver event which m eets the criteria for a “ medically significant ” event should follow the 
standard procedures for SAE reporting as described in Section 7.2.
Every  liver event as defined in Table 15-1-Appendix 3should be followed up by [CONTACT_351998] p ersonal at the trial site, as summarized below and detailed in 
Table 15-2-Appendix 3 .
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospi[INVESTIGATOR_18539]
A causalit y assessment of the liver event via exclusion of alternative causes 
(e.g., disease, co-medications)
An investigation of the liver event which needs to be followed until resolution
[COMPANY_001] Confidential Page 69
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded as appropriate in the CRF.
7.[ADDRESS_437835] be reported to [COMPANY_001] within 24 hours of learning of its occurren ce. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregna ncy should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_351999] & PS Department. Pregnancy  follow -up should be recorded on 
the same form and should include an assessment of the possible relationship to the 
invest igational/study  treatment any pregnancy outcome. Any SAE experienced during 
pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
7.5 Prospective suicidality  assessment
The Columbia -Suicide Severity  Rating Scale (C-SSRS), a questionnaire that prospectively 
assesses Suicidal Ideation and Suicidal Behavior using a semi -structured interview to probe 
patient responses, has to be administered.
If at any assessment after screening and/or baseline the score is 4 or above on the Suicidal 
Ideation item or any “yes” on the Suicidal Behavior item, the patient must be referred to a 
health care professional for further assessment and/or treatment. The decision on whether the 
study  treatment should be discontinued is to be taken by [CONTACT_352000].
7.6 Early phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required s will be made jointly  between medicall y 
qualified personnel representing the Sponsor and Investigator . Such evaluations may occur 
verball y, but the outcome and key discussion points will be summarized in writing (e-mail) 
and made available to both Sponsor and all Investigator(s). Criteria pertaining to stoppi[INVESTIGATOR_90348] /treatment or adapting the study  design are presented above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by [CONTACT_50106]) of any 
new, clinically  relevant safet y informat ion reported from another site during the conduct of 
the study  in a timel y manner.
[COMPANY_001] Confidential Page 70
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
8 Data revie w and database management
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will revie w the protocol and CRFs with the invest igators and their staff. 
During the study , the field monitor will visit the site regularl y to check the completeness of 
patient records, the accuracy  of entries on the CRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_102] (a signed copy  is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and the recording of data that will be used for all primary  and safet y 
variables. Additional checks of the consistency of the source data with the CRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the patients will be disclosed.
8.[ADDRESS_437836] an external originating source (either written or 
electronic). T he CRF is not considered as source.
[COMPANY_001] Confidential Page 71
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
8.[ADDRESS_437837] that allows its accurate reporting, 
interpretation and verification.
[COMPANY_001] staff or CRO working on [COMPANY_001]’s behalf will review the data entered into the 
eCRFs by [CONTACT_352001] y required corrections or additions. Queries are sent to the investigational site using 
an electronic data query . Designated investigator site staff is required torespond to the query 
and confirm or correct the data. If the electronic query  system is not used, a paper Data Quer y 
Form will be sent (e.g. ,fax, e -mail) to the site. Site personnel will complete and sign the copy , 
then send it (with original signature) back to [COMPANY_001] staff who will make the correction to 
the database.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronically  to 
[COMPANY_001] (or a designate d CRO).
8.[ADDRESS_437838] (DSMB ) has been assembled for this compound to monitor
safet y data for the combined First In Man and Proof of Concept study . This committee is 
autonomous and comprises one external expert as well as select ed[COMPANY_001] associates who 
have subject matter expertise in auditory  and vestibular clinical diagnosis, as well as general
expertise in safet y monitoring, monitoring of clinical trials, and statistical analysis and data
visualization.
The DSMB will convene as outlined in the DSMB Charter to review adverse events, 
including clinical laboratory  data, pure tone audiometry  assessment and vestibular safet y 
assessment will be continuously  reviewed.
8.5 Adjudication Committee
Not required.
Commercially Confidential Information
[COMPANY_001] Confidential Page 72
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
9 Data analy sis
9.1 Analysis sets
For all anal ysis sets, patients will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all patients that received any  study  drug.
The PD analy sis set will include all patients with available PD data and no protocol deviations 
with relevant impact on PD data.
9.2 Patient demographics and other baseline characteristics
All data for background and demographic variables will be listed by [CONTACT_352002]. Summary  statistics will be provided.by  [CONTACT_1570].
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other rele vant information will be listed by [CONTACT_90217].
9.3 Treatments (study  drug, rescue medication, other concomitant 
therapi[INVESTIGATOR_014], compliance)
Data for study  drug administration (rescue medication) and concomitant therapi[INVESTIGATOR_351957].
9.4 Analysis of the primary  variable(s)
The primary  aim of this study  is to determine the effect of a single injection of CGF166 on 
pure tone audiometry  measured at 4 week intervals from month 1 to month 6after surgery . 
The second primary  objective is to assess the safety  and tolerability  of IL CGF166.
9.4.1 Variable(s)
The primary  analysis variable is the audiometric threshold measured on a dB HL (hearing loss) 
scale at these f requencies : 0.125, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12.5, 14, 16 kHz.
9.4.2 Statistical model, hypothesis, and method of analy sis
Tone thresholds will be analy zed for each frequency  tested separatel y. 
For pure tone audiometry , a measure that depends on a patient being able to hear a tone, the 
following imputation will be done: If a patient is unable to hear the tone at a specific 
frequency it can be inferred that the threshold value exceeds the upper limit of the machine. In 
this case the value will be imputed to 5dB above the upper limit of the machine.
All pure tone audiometry  air conduction threshold data will be listed and graphicall y 
display ed by [CONTACT_4676], infusion volume, frequency, and visit/time. Summary statistics will be 
provided by [CONTACT_351972], frequency , ear and visit/time. Change from baseline of the 
thresholds (me an of screening and baseline visit) will also be summarized by  [CONTACT_351972], 
frequency , ear and visit/time. 
[COMPANY_001] Confidential Page 73
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
In addition, safet y and tolerability  is a co -primary  endpoi nt, and will be analyzed as in 
Section 9.5.2 (Safet y).
9.4.3 Handling of missing values/censoring/discontinuations
All missing data, which are missing due to an assessment not having been made, will be 
treated as “missing at random”. Patients with partial data will be included in the primary 
analysis. Where a missing data value occurs, this will be set to missing in th e anal ysis. For the 
combined baseline of screening and baseline data, where only screening or baseline data is 
available, this value will be taken as the baseline. If no pre-treatment data is available, the 
subject will be excluded from the anal ysis when c omparing the change to pre -treatment values. 
Pure tone audiometry  values which are missing because the hearing threshold exceeded the 
upper limit of the machine will be imputed with the value of 5dB above the upper limit of the 
machine.
9.4.4 Supportive analy se
s
Not applicable.
9.5 Analysis of secondary   variables
Secondary  variables will be anal yzed descriptively.
9.5.1 Efficacy
Secondary  efficacy  variables will be reported descriptively .
9.5.2 Safety
Vital signs
All vital signs data will be listed by [CONTACT_3148] , patient, and visit/time and if ranges are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided by [CONTACT_10659]/time.
ECG evaluations
All ECG data will be listed by  [CONTACT_3148], patient and v isit/time, abnormalities will be flagged. 
Summary  statistics will be provided by  [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_3148], patient, and visit/time and if normal ranges are 
available abnormali ties will be flagged. Summary  statistics will be provided by [CONTACT_103913]/time.
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_117912].
Commercially Confidential 
Information
[COMPANY_001] Confidential Page 74
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
The number and percentage of patients with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_3148]. A patient with multiple adverse events 
within a body  system is only counted once towards the total of this body  system.
Exact 95% binomial confidence intervals may be provided for AErates. If a dose-related 
safet y signal is suspected, this may be confirmed by a permutation contrast test t using the 
nominal dose level as contrast.
Other safety  evaluations
Not applicable .
9.6 Sample size calculation
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 75
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
9.7 Power for analy sis of key  secondary  variables
Not applicable.
9.8 Interim analy ses
No interim ana lyses are planned in the study .
10 Ethical consideration
10.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 
21, and Japanese Ministry  of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki.
10.2 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapa ble of doing 
Commercially Confidential Information
[COMPANY_001] Confidential Page 76
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
so, after such consent has been provided by a legally  acceptable representative of the patient. 
In cases where the patient’s representative gives consent, the patient should be informed about 
the study  to the extent possible given his/her unde rstanding. If the patient is capable of doing 
so, he/she should indicate assent by [CONTACT_18684] a separate assent form. Informed consent must be obtained before 
conducting any study -specific procedu res (i.e. ,all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the patient source 
documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 
considered appropriate for this study . Any  changes to the proposed consent form suggested by  
[CONTACT_90219]/IEC, and a copy
of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval.
Women of child bearing potential should be informed that taking the study  drug may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study  they must adhere to the contraception requirement for the duration 
of the study . If there is any question that the patient will not reliably  comply , they should not 
be entered in the study .
The study  includes an optional pharmacogenetic component which requires a separate 
signature [CONTACT_352005]. It is required as part of this protocol that the 
Investigator presents this option to the patient. The process for obtaining consent should be 
exactly  the same as described above for the main informed consent.
Declining to participate in these pharmacogenetic assessments will in no way affect the 
patient’s ability  to participate in the main research study .
In the event that [COMPANY_001] wants to perform testing on the samples that are not described in this 
protocol, additional Institutional Review Board and/or Ethics Committee approval will be obtained.
10.3 Responsibilities of the investigator and IRB/IEC
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/ Independent Ethics Committee /Research Ethics 
Board (IRB/I EC/REB) before study  start. A signed and dated statement that the protocol and 
informed consent have been approv ed by [CONTACT_1201]/IEC/REB must be given to [COMPANY_001] before 
study  initiation. Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_144984]/her agreement to conduct the study in accordance with these documents and all of 
the instructions and procedures found in this protocol and to give access to all relevant data and 
records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical Qualit y Assurance representatives, 
designated agents of [COMPANY_001], IRBs/IECs/REBs, and regulatory  authorities as required. If an 
inspection of the clinical site is requested by a regulatory  authority , the investigator must inform 
[COMPANY_001] immediately  that this request has been made.
10.4 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
[COMPANY_001] Confidential Page 77
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
finalization of the study  report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
[ADDRESS_437839] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
11.[ADDRESS_437840] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, [COMPANY_001] should be notified of this action and the Health Authorities 
(where required) and the IRB/IEC/REB at the study  site should be informed within 
10working day s or less, if required b y local regulation.
[COMPANY_001] Confidential Page 78
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
[ADDRESS_437841].
Agrawal Y, Platz EA, Niparko JK (2008) Prevalence of hearing loss and differences b y 
demographic characteristics among US adults: data from the National Health and Nutrition 
Examination Survey , 1999 -2004. Arch Intern Med. 16:1522 -1530.
Agrawal Y, Schubert MC, Migliaccio AA, et al (2013) Evaluation of Quantitative Head 
Impulse Testing Using Search Coils vs. Video -oculography  in Older Individuals. Otol 
Neurotol. 
Balkan y TJ, Connell SS, Hodges AV, et al (2006) Conservation of residual acoustic hearing 
after cochlear implantation. Otol Neur otol. 2006 Dec;27(8):[ADDRESS_437842] RH , et al (2011) .Implications of minimizing trauma during 
conventional cochlear implantation. Otol.Neurotol., 32, (6) 962
-968.
Clark JG (1981) Uses and abuses of hearing loss classification. Am erican Speech- Language -
Hearing Association 2475(81 -230):493-500.
Cremer PD, Halmagy i GM, Aw ST, et al (1998) . Semicircular canal plane head impulses 
detect absent function of individual semicircular canals. Brain ;121 ( Pt 4):699-716.
Gifford RH, Shallop JK, Peterson AM, et al (2008) Speech recognition materials and ceiling 
effects: considerations for cochlear impla nt programs. Audiology  & Neurotology  13:193-205.
Halmagy i GM and Curthoy s IS(1988) A clinical sign of canal paresis. Arch Neurol. 1988 
Jul;45(7):737 -9.
MacDougall HG, McGarvie LA, Halmagy i GM, et al (2013) The video Head Impulse Test 
(vHIT) detects vertical semicircular canal d ysfunction. PL OS One. 2013 Apr 22;8(4):e61488. 
doi: 10.1371/journal.pone.0061488.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 79
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Nilsson M, S oliSD, Sullivan JA , et al (1994) “Development of the Hearing in Noise Test for 
the m easurement of speech reception thresholds in quiet and in noise.” J Acoust Soc Am 
95(2): 1085-1099.
Peterson GE and Lehiste I (1962) “Revise d CNC lists for auditory  tests.” J Speech Hear 
Disord 27: 62-70.
Rio C, Dikkes P, L iberman MC, et al (2002) Glial fibrillary  acidic protein expression and 
promoter activit y in the inner ear of developi[INVESTIGATOR_351958]. J.Comp Neurol., 442, (2) 
156-162.
Schlecker C, Praetorius M, Brough DE, et al (2011) Selective atonal gene delivery  improves 
balance function in a mouse model of vestibular disease. Gene Ther. 18, 884 -
890.
Skarzy nski H, Furmanek MI , Pi[INVESTIGATOR_351959] A, et al (2007) [Value of multidetector computed 
tomograph y in detection of congenital inner ear malformati ons and its usefulness in 
qualification for cochlear implantation]. Otolaryngologia Polska 61 (4):585-90.
Spahr AJ andDorman MF (2004) “Performance of subjects fit with the Advanced Bionics CII 
and Nucleus 3G cochlear implant d evices.” Arch Otolary ngol Head Neck Surg 130(5): 
624-628.
Staecker H, Brantley  J, Hsu C , et al (2011 ) RD-2011 - [ZIP_CODE]: CGF166 In Vivo Dose Response 
to the I nner Ear in a Mouse Model of Vestibular Hy pofunction .
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 80
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
13 Appendix 1 : Sample Log table –all matrices
Commercially Confidential Information
[COMPANY_001] Confidential Page 81
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 82
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 83
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
15 Appendix 3: Liver event definitions and follo w-up 
requirements
Table 15-1 Liver Event Definitions
Definition / threshold
Adverse event of special 
interest
Laboratory values ALT or AST > [ADDRESS_437843]
ALP > [ADDRESS_437844]
TBL > 1.[ADDRESS_437845]
Medically significant event 
(SAE)
Laboratory values ALT or AST > [ADDRESS_437846] (with or without TBL > [ADDRESS_437847] [mainly 
conjugated fraction])
ALP > [ADDRESS_437848] (with or without TBL > [ADDRESS_437849] [mainly conjugated 
fraction])
TBL > [ADDRESS_437850]
Potential Hy’s Law cases (defined as ALT/AST > [ADDRESS_437851] and 
TBL > [ADDRESS_437852] [mainly conjugated fraction] without notable 
increase in ALP to > [ADDRESS_437853])
Adverse events Any clinical event of jaundice (or equivalent term)
ALT or AST > [ADDRESS_437854] accompanied by [CONTACT_352003], fatigue, 
abdom inal pain, nausea, or vomiting , or rash with eosinophilia
Any event that links to a preferred term (PT) in the MedDRA 
dictionar y falling under the SMQ sub -module “Drug -related hepatic 
disorders – severe events only”* or any “Hy’s law case” PT
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
[COMPANY_001] Confidential Page 84
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Table 15-2 Liver Event Follo w Up Requirements
Criteria Event type Actions required Follow -up monitoring
Potential Hy’s 
Law caseaMedically 
significantHospi[INVESTIGATOR_18552], if clinically 
appropriate
Report to [COMPANY_001] as an SAE
Establish causalityALT, AST, TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
ALT or A ST
> [ADDRESS_437855], TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
> 5 to ≤ [ADDRESS_437856], TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
> [ADDRESS_437857], TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
> 3 to ≤ [ADDRESS_437858]
(patient is 
asymptomatic)AESI Central laboratory to report to 
Investigator & [COMPANY_001]
Repeat LFT once or twice in the 
week
If elevation persists, establish 
causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ [ADDRESS_437859]
(patient is 
asymptomatic)N/A Repeat LFT at next visit
ALP (isolated)
> [ADDRESS_437860] Medically 
significantRepeat LFT within 48 hours
If elevation persists, report to 
[COMPANY_001] as an SAE
Establish causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
> 2 to ≤[ADDRESS_437861]
(patient is 
asymptomatic)AESI Central laboratory to report to 
Investigator & [COMPANY_001]
Repeat LFT once or twice in the 
week
If elevation persists, establish 
causalityInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ 2 x UL N
(patient is 
asymptomatic)N/A Repeat LFT at next visit
[COMPANY_001] Confidential Page 85
Amended Protocol Version v06 ( Clean ) Protocol No. CCGF166X2201
Criteria Event type Actions required Follow -up monitoring
TBL (isolated)
> [ADDRESS_437862], TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
Test for hemoly sis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirec t] 
bilirubin)
> 1.5 to ≤ [ADDRESS_437863]
(patient is 
asymptomatic)AESI Central laboratory to report to 
[COMPANY_001]
Repeat LFT once or twice in the 
week
If elevation persists, establish 
causalityinvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
≤ 1.[ADDRESS_437864]
(patient is 
asymptomatic)N/A Repeat LFT at next visit
Preferred terms
Jaundice Medically 
significantHospi[INVESTIGATOR_351960], AST, TBL, Alb, PT, 
ALP and γGT until 
resolutionc(frequency at 
investigator discretion)
“Drug -related 
hepatic 
disorders - severe 
events only ” SMQ 
AEMedically 
significanthospi[INVESTIGATOR_351961]/AST > [ADDRESS_437865] and TBL > [ADDRESS_437866] but with no notable increase in ALP to > [ADDRESS_437867]
bGeneral malaise, fatigue, abdominal pain, nausea, or vomiting, rash with eosinophilia
cResolution is defined as an outcome of one of the following: return to baseline v alues, stable values at three 
subsequent monitoring visits at least 2 weeks apart, remain at elevated level after a maximum of 6 months, liver 
transplantation, and death.